Behavioral Symptoms  >>  bupropion sustained-release  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bupropion sustained-release / Generic mfg.
NCT01138007: A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)

Completed
3
572
Japan, RoW
323U66 SR 150 mg tablet, 323U66 SR 150 mg placebo tablet
GlaxoSmithKline
Depressive Disorder, Major
08/12
08/12

Download Options